Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Immutep announces that ImmuFact IMP321 induces activation of a wide range of human effector cyto...
Research paper describes IMP321's potency as a new immunopotentiator in cancer patients

Orsay, September 17, 2007 - Immutep S.A., a biopharmaceutical company specialised in immunostimulatory and immunomodulatory treatments of cancer and infectious or autoimmune disease, announced today the publication of a research paper showing that its lead product, IMP321, induces activation of a wide range of human effector cytotoxic cells.

ImmuFact(R) IMP321 is a potent natural human immunostimulatory factor designed to amplify the T cell immune response. It can be used either as an immunopotentiator in therapeutic vaccines or alone at higher doses as a monotherapy or in combination with chemotherapy. Six clinical trials have been initiated with ImmuFact IMP321 in the last 30 months.

Immutep's ImmuFact research team carried out the study described in the research paper at its laboratories near Paris.

The principal anti-tumour immune response is mediated through the activation of type 1 cytotoxic (Tc1) CD8+ T cells, NK cells and monocytes/macrophages. The research team investigated the potency of IMP321 at inducing such a cytotoxic-type response in short term ex vivo assays on human blood cells.

The research team found that IMP321, a soluble recombinant form of the human LAG-3 protein, binds to all circulating dendritic cells and a fraction of MHC class II+ monocytes. Four hours after addition of IMP321 to blood cells these antigen-presenting cells (APC) produce cytokines important for initiating the immune response. At 18 hours, following this activation of the APC, a significant number of CD8+ T cells and NK cells are fully activated in their turn and produce Tc1 cytokines such as IFN-y or TNF-a. Similar induction was observed in metastatic cancer patients.

In contrast to IMP321, TLR agonists, another class of immunostimulatory factors, all induce the immunosuppressive IL-10 cytokine, and are therefore unable to achieve the Tc1 IFN-y+ response that is crucial to an effective anti-tumoral effect.

Thus, IMP321 has properties that confirm its uniqueness and potency as a new immunopotentiator in cancer patients.

'It is remarkable that 92 per cent of blood donors or patients respond at clinically-significant levels to a first short exposure of IMP321.' said Chrystelle Brignone, ImmuFact Project Manager and first author of the paper.

'This timely and orderly activation of both innate and adaptive immunity by this potent endogenous APC activating agent shows great promise for a new era of more effective immunotherapies in cancer patients,' said Frédéric Triebel, Immutep's Scientific and Medical Director. 'Similar strong induction of both innate and adaptive immunity effector arms has been already observed with IMP321 administered for six months in metastatic cancer patients, without side effects. This shows that immune activation could be safely induced over a long period of time to high levels using this unique and natural signalling pathway into APC.'

For further information please visit the web-site or e-mail John Hawken, CEO, at

Notes to Editors:

The Published Paper
'A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells', Chrystelle Brignone, Caroline Grygar, Manon Marcu, Knut Schäkel, and Frédéric Triebel, Journal of Immunology 2007 179: 4202-4211

The LAG-3 Immune Control Mechanism
The Lymphocyte Activation Gene-3 (LAG-3) immune control mechanism plays a role in both the upregulation of the immune system through antigen presenting cells like dendritic cells and in the downregulation of the immune system through different types of lymphocytes. The lymphocyte activation gene-3 (LAG-3 or CD223) binds to the MHC class II molecule which is at the centre of immune response induction. LAG-3 is evolutionarily related to CD4 and has retained an affinity 2 log higher than CD4 for their common ligand, MHC class II molecules on antigen presenting cells such as dendritic cells. LAG-3 was di

Publisher Contact Information:

Immutep S.A.

Company profile of Immutep S.A.
Past press releases of Immutep S.A..


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 15€2.4MMaterials
Nov 15€6.0MArtificial Intelligence
Nov 15€3.5MSoftware development
Nov 15N/AInternet services
Nov 14€4.5MOther Software
Nov 14€4.7MBusiness applications
Nov 14€9.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.